Insider Selling: Castle Biosciences (NASDAQ:CSTL) Insider Sells 6,214 Shares of Stock

Castle Biosciences, Inc. (NASDAQ:CSTL) insider Derek Maetzold sold 6,214 shares of the company’s stock in a transaction that occurred on Wednesday, July 1st. The stock was sold at an average price of $24.29, for a total transaction of $150,938.06. Following the sale, the insider owned 21,479 shares in the company, valued at $521,724.91. The trade was a 22.44% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Castle Biosciences Stock Up 0.4%

NASDAQ:CSTL traded up $0.10 during mid-day trading on Monday, hitting $24.21. The stock had a trading volume of 187,688 shares, compared to its average volume of 397,864. Castle Biosciences, Inc. has a twelve month low of $14.59 and a twelve month high of $44.28. The stock has a 50-day simple moving average of $21.54 and a two-hundred day simple moving average of $28.56. The company has a current ratio of 6.75, a quick ratio of 6.53 and a debt-to-equity ratio of 0.02. The company has a market capitalization of $734.29 million, a PE ratio of -55.02 and a beta of 1.00.

Castle Biosciences (NASDAQ:CSTL) last announced its quarterly earnings data on Wednesday, May 6th. The company reported ($0.49) earnings per share for the quarter, meeting analysts’ consensus estimates of ($0.49). The business had revenue of $84.23 million for the quarter, compared to analyst estimates of $79.23 million. Castle Biosciences had a negative net margin of 3.78% and a negative return on equity of 2.77%. On average, equities research analysts anticipate that Castle Biosciences, Inc. will post -1.56 EPS for the current year.

Analysts Set New Price Targets

A number of research analysts have recently commented on the company. Canaccord Genuity Group dropped their price objective on Castle Biosciences from $50.00 to $40.00 and set a “buy” rating on the stock in a report on Monday, April 20th. KeyCorp set a $35.00 target price on Castle Biosciences in a research note on Friday, May 29th. Zacks Research downgraded Castle Biosciences from a “strong-buy” rating to a “hold” rating in a report on Tuesday, May 26th. Weiss Ratings cut shares of Castle Biosciences from a “sell (d-)” rating to a “sell (e+)” rating in a report on Monday, June 1st. Finally, Roth Mkm started coverage on shares of Castle Biosciences in a research report on Wednesday, June 24th. They set a “buy” rating and a $40.00 price objective for the company. One equities research analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $42.43.

Institutional Investors Weigh In On Castle Biosciences

Several large investors have recently modified their holdings of the company. Vanguard Group Inc. grew its position in shares of Castle Biosciences by 1.3% during the fourth quarter. Vanguard Group Inc. now owns 2,199,829 shares of the company’s stock worth $85,573,000 after acquiring an additional 27,511 shares during the last quarter. RTW Investments LP acquired a new stake in Castle Biosciences during the 4th quarter worth $82,283,000. Principal Financial Group Inc. grew its position in Castle Biosciences by 0.7% during the 4th quarter. Principal Financial Group Inc. now owns 1,807,644 shares of the company’s stock worth $70,317,000 after purchasing an additional 13,289 shares during the last quarter. Portolan Capital Management LLC grew its position in Castle Biosciences by 1.7% during the 3rd quarter. Portolan Capital Management LLC now owns 1,515,111 shares of the company’s stock worth $34,499,000 after purchasing an additional 25,539 shares during the last quarter. Finally, Dimensional Fund Advisors LP increased its stake in Castle Biosciences by 7.0% in the third quarter. Dimensional Fund Advisors LP now owns 1,474,089 shares of the company’s stock valued at $33,564,000 after purchasing an additional 96,084 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Castle Biosciences Company Profile

Castle Biosciences, Inc is a molecular diagnostics company specializing in the development and commercialization of prognostic and diagnostic tests for patients with dermatologic conditions. The company’s proprietary portfolio of genomic assays is designed to improve risk assessment and guide clinical decision-making for individuals with skin cancers and other skin-related diseases. By combining genomic data with advanced statistical algorithms, Castle Biosciences seeks to provide actionable insights that help physicians tailor treatment plans and monitoring strategies.

The company’s flagship test, DecisionDx-Melanoma, evaluates the probability of metastasis in patients diagnosed with cutaneous melanoma, supporting more personalized surveillance and therapeutic approaches.